MDXG Stock Analysis: MiMedx | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 581m USD | 12M Return: -35.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.26M
Qual. Beats: -1
Rev. Trend: 95.9%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
MiMedx Group, Inc. is a U.S.-based biotechnology company that develops and commercializes placental tissue allografts processed through its proprietary PURION technology, which preserves the biological and regulatory proteins of human placental tissue. The company operates two main product lines: wound care offerings (including EPIFIX and EPICORD) and surgical and other products (such as AMNIOFIX and AMNIOBURN), serving wound care, burn treatment, and surgical applications across lower extremity repair, plastic surgery, vascular surgery, and orthopedic procedures. Products are sold in the United States through a direct sales force, independent sales agents, individual customers, and independent distributors, and the company maintains a strategic alliance with Vaporox, Inc. for wound care promotion. Founded in 2006 and headquartered in Marietta, Georgia, MiMedx fits within the broader regenerative medicine segment of healthcare, where companies leverage human tissue-based biologics rather than synthetic or small-molecule approaches to address tissue repair and healing. As a small-cap stock in the biotechnology sub-industry, the companys revenue is closely tied to reimbursement decisions, clinical adoption of placental allografts, and ongoing regulatory scrutiny of tissue-based products.
- Wound care segment revenue grows on EPIFIX market penetration
- Surgical recovery sales expand in orthopedic and plastic surgery applications
- Regenerative tissue competition pressures product pricing and margins
| Net Income: 30.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA -0.69 > 1.0 |
| NWC/Revenue: 50.27% < 20% (prev 44.69%; Δ 5.58% < -1%) |
| CFO/TA 0.23 > 3% & CFO 70.6m > Net Income 30.7m |
| Net Debt (-142.2m) to EBITDA (57.3m): -2.48 < 3 |
| Current Ratio: 5.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (148.4m) vs 12m ago -0.82% < -2% |
| Gross Margin: 81.04% > 18% (prev 81.88%; Δ -0.84% > 0.5%) |
| Asset Turnover: 134.5% > 50% (prev 130.3%; Δ 4.18% > 0%) |
| Interest Coverage Ratio: 21.28 > 6 (EBIT TTM 44.0m / Interest Expense TTM 2.07m) |
| A: 0.63 (Total Current Assets 240.3m - Total Current Liabilities 44.5m) / Total Assets 308.7m |
| B: -0.17 (Retained Earnings -53.5m / Total Assets 308.7m) |
| C: 0.15 (EBIT TTM 44.0m / Avg Total Assets 289.5m) |
| D: 3.70 (Book Value of Equity 242.9m / Total Liabilities 65.7m) |
| Altman-Z'' = 8.50 = AAA |
| DSRI: 0.67 (Receivables 46.0m/62.3m, Revenue 389.4m/352.4m) |
| GMI: 1.01 (GM 81.88% / 81.04%) |
| AQI: 0.94 (AQ_t 0.21 / AQ_t-1 0.22) |
| SGI: 1.11 (Revenue 389.4m / 352.4m) |
| TATA: -0.13 (NI 30.7m - CFO 70.6m) / TA 308.7m) |
| Beneish M = -3.26 (Cap -4..+1) = AA |
As of July 08, 2026, the stock is trading at USD 4.20 with a total of 1,477,829 shares traded. Over the past week, the price has changed by +7.42%, over one month by +13.51%, over three months by +8.81% and over the past year by -35.19%.
Current recommended Stop Loss: 3.90 (which is 7.1% or 2.1 ATR below the current price).
MiMedx has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy MDXG.
- StrongBuy: 5
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 6.6 | 57.1% |
P/E Trailing = 19.5
P/E Forward = 19.5313
P/S = 1.4917
P/B = 2.3942
P/EG = 2.875
Revenue TTM = 389.4m USD
EBIT TTM = 44.0m USD
EBITDA TTM = 57.3m USD
Long Term Debt = 16.1m USD (from longTermDebt, last quarter)
Short Term Debt = 1.50m USD (from shortTermDebt, last quarter)
Debt = 17.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -142.2m USD (calculated: Debt 17.6m - CCE 159.8m)
Enterprise Value = 438.7m USD (580.9m + Debt 17.6m - CCE 159.8m)
Interest Coverage Ratio = 21.28 (Ebit TTM 44.0m / Interest Expense TTM 2.07m)
EV/FCF = 6.70x (Enterprise Value 438.7m / FCF TTM 65.5m)
FCF Yield = 14.93% (FCF TTM 65.5m / Enterprise Value 438.7m)
FCF Margin = 16.82% (FCF TTM 65.5m / Revenue TTM 389.4m)
Net Margin = 7.88% (Net Income TTM 30.7m / Revenue TTM 389.4m)
Gross Margin = 81.04% ((Revenue TTM 389.4m - Cost of Revenue TTM 73.8m) / Revenue TTM)
Gross Margin QoQ = 70.56% (prev 83.86%)
Tobins Q-Ratio = 1.42 (Enterprise Value 438.7m / Total Assets 308.7m)
Interest Expense / Debt = 11.75% (Interest Expense 2.07m / Debt 17.6m)
Taxrate = 27.47% (11.6m / 42.3m)
NOPAT = 31.9m (EBIT 44.0m * (1 - 27.47%))
Current Ratio = 5.39 (Total Current Assets 240.3m / Total Current Liabilities 44.5m)
Debt / Equity = 0.07 (Debt 17.6m / totalStockholderEquity, last quarter 242.9m)
Debt / EBITDA = -2.48 (Net Debt -142.2m / EBITDA 57.3m)
Debt / FCF = -2.17 (Net Debt -142.2m / FCF TTM 65.5m)
Total Stockholder Equity = 238.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.60% (Net Income 30.7m / Total Assets 308.7m)
RoE = 12.86% (Net Income TTM 30.7m / Total Stockholder Equity 238.8m)
RoCE = 17.26% (EBIT 44.0m / Capital Employed (Equity 238.8m + L.T.Debt 16.1m))
RoIC = 12.96% (NOPAT 31.9m / Invested Capital 246.2m)
WACC = 8.99% (E(580.9m)/V(598.5m) * Re(9.0%) + D(17.6m)/V(598.5m) * Rd(11.75%) * (1-Tc(0.27)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 28.89 | Cagr: 0.11%
[DCF] Terminal Value 74.61% ; FCFF base≈63.0m ; Y1≈68.8m ; Y5≈86.2m
[DCF] Fair Price = 8.92 (EV 1.19b - Net Debt -142.2m = Equity 1.33b / Shares 148.9m; r=8.99% [WACC]; 5y FCF grow 10.57% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.07 | # QB: -1
Revenue Correlation: 95.94 | Revenue CAGR: 11.43% | SUE: -0.98 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.03 | Chg30d=N/A | Revisions=-40% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.00 | Chg30d=N/A | Revisions=-40% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.07 | Chg30d=+6.67% | Revisions=-40% | GrowthEPS=-115.6% | GrowthRev=-35.6%
EPS next Year (2027-12-31): EPS=0.14 | Chg30d=+16.98% | Revisions=-40% | GrowthEPS=+304.8% | GrowthRev=+12.4%
[Analyst] Revisions Ratio: -73% (up=0, down=8)